Dr. Pei-Rong Ding is currently a Professor and Chief Surgeon in the Department of Colorectal Cancer at Sun Yat-sen University Cancer Center (SYSUCC). He has extensive experience and expertise in developing treatment for colorectal cancer, gastrointestinal stromal tumor and gastrointestinal neuroendocrine tumor. He is skilled at treating primary, metastatic, and recurrent colorectal cancer. His expertise in minimally invasive surgery enables him to remove tumors without causing significant trauma to the patient. He is skilled in nerve-sparing surgical techniques that preserve sphincter, bladder, and sexual function in rectal surgery. Dr. Ding’s primary research interests include the screening and management of hereditary colorectal cancer and early-onset colorectal cancer, and optimization of neoadjuvant therapy for locally advanced rectal cancer. He is now leading several clinical trials to explore a better treatment models for rectal cancer and Lynch Syndrome. He has published more than 30 papers in some celebrated journal such as JNCI, Ann Surg, Eur J Can, theranostics, and Oncoimmunology.

Screening and management of hereditary colorectal cancer and early-onset colorectal cancer; optimization of neoadjuvant therapy for locally advanced rectal cancer; impact of microenvironment on immunotherapy of colorectal cancer.

2005/9-2010/7, Sun Yat-Sen University, Oncology, PhD, Supervisor: Pan Zhizhong

1997/9-2002/7, Sun Yat-Sen University, Clinical Medicine, Bachelor

1. Liu D. X., Li D. D., He W., Ke C. F., Jiang W., Tang J. H., Kong L. H., Li Y., Sui Q. Q., Xiao B. Y., Li W. R., Hong Z. G., Xu R. H., Pan Z. Z., Zhang X. S., Ding P. R. PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer. Oncoimmunology 9:1711650, 2020

2. Sui Q., Zheng J., Liu D., Peng J., Ou Q., Tang J., Li Y., Kong L., Jiang W., Xiao B., Chao X., Pan Z., Zhang H., Ding P. R. Dickkopf-related protein 1, a new biomarker for local immune status and poor prognosis among patients with colorectal liver Oligometastases: a retrospective study. BMC Cancer 19:1210, 2019

3. Sui Q. Q., Jiang W., Wu X. D., Ling Y. H., Pan Z. Z., Ding P. R. A frameshift mutation in exon 19 of MLH1 in a Chinese Lynch syndrome family: a pedigree study. J Zhejiang Univ Sci B 20:105-108, 2019

4. Jiang W., Cai M. Y., Li S. Y., Bei J. X., Wang F., Hampel H., Ling Y. H., Frayling I. M., Sinicrope F. A., Rodriguez-Bigas M. A., Dignam J. J., Kerr D. J., Rosell R., Mao M., Li J. B., Guo Y. M., Wu X. Y., Kong L. H., Tang J. H., Wu X. D., Li C. F., Chen J. R., Ou Q. J., Ye M. Z., Guo F. M., Han P., Wang Q. W., Wan D. S., Li L., Xu R. H., Pan Z. Z., Ding P. R., Written on behalf of A. M. E. Colorectal Cancer Cooperative Group Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: High prevalence and unique molecular features. Int J Cancer, 2018

5. Tang J., Jiang W., Liu D., Luo J., Wu X., Pan Z., Ding P., Li Y. The comprehensive molecular landscape of the immunologic co-stimulator B7 and TNFR ligand receptor families in colorectal cancer: immunotherapeutic implications with microsatellite instability. Oncoimmunology 7:e1488566, 2018

6. Mai D., Ding P., Tan L., Zhang J., Pan Z., Bai R., Li C., Li M., Zhou Y., Tan W., Zhou Z., Li Y., Zhou A., Ye Y., Pan L., Zheng Y., Su J., Zuo Z., Liu Z., Zhao Q., Li X., Huang X., Li W., Wu S., Jia W., Zou S., Wu C., Xu R. H., Zheng J., Lin D. PIWI-interacting RNA-54265 is oncogenic and a potential therapeutic target in colorectal adenocarcinoma. Theranostics 8:5213-5230, 2018

7. Liu G. C., Liu R. Y., Yan J. P., An X., Jiang W., Ling Y. H., Chen J. W., Bei J. X., Zuo X. Y., Cai M. Y., Liu Z. X., Zuo Z. X., Liu J. H., Pan Z. Z., Ding P. R. The Heterogeneity Between Lynch-Associated and Sporadic MMR Deficiency in Colorectal Cancers. J Natl Cancer Inst, 2018

8. Yu X., Wang Q. X., Xiao W. W., Chang H., Zeng Z. F., Lu Z. H., Wu X. J., Chen G., Pan Z. Z., Wan D. S., Ding P. R., Gao Y. H. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study. Cancer Commun (Lond) 38:24, 2018

9. Fan W. H., Xiao J., An X., Jiang W., Li L. R., Gao Y. H., Chen G., Kong L. H., Lin J. Z., Wang J. P., Pan Z. Z., Ding P. R. Patterns of recurrence in patients achieving pathologic complete response after neoadjuvant chemoradiotherapy for rectal cancer. J Cancer Res Clin Oncol 143:1461-1467, 2017

10. Tang J., Wu X., Bai Y., Gao Y., Jiang W., Kong L., Lin J., Wan D., Pan Z., Ding P. Long-Term Outcome of Oxaliplatin and Capecitabine (XELOX) Concomitant with Neoadjuvant Radiotherapy and Extended to the Resting Period in High Risk Locally Advanced Rectal Cancer. J Cancer 9:1365-1370, 2018

11. Qiu B., Ding P. R., Cai L., Xiao W. W., Zeng Z. F., Chen G., Lu Z. H., Li L. R., Wu X. J., Mirimanoff R. O., Pan Z. Z., Xu R. H., Gao Y. H. Outcomes of preoperative chemoradiotherapy followed by surgery in patients with unresectable locally advanced sigmoid colon cancer. Chin J Cancer 35:65, 2016

12. Liu G. C., Yan J. P., He Q., An X., Pan Z. Z., Ding P. R. Effect of Neoadjuvant Chemoradiotherapy with Capecitabine versus Fluorouracil for Locally Advanced Rectal Cancer: A Meta-Analysis. Gastroenterol Res Pract 2016:1798285, 2016

13. Lin J., Peng J., Qdaisat A., Li L., Chen G., Lu Z., Wu X., Gao Y., Zeng Z., Ding P., Pan Z. Severe weight loss during preoperative chemoradiotherapy compromises survival outcome for patients with locally advanced rectal cancer. J Cancer Res Clin Oncol 142:2551-2560, 2016

14. Wang Q. X., Li S. H., Zhang X., Xie L., Cai P. Q., An X., Pan Z. Z., Ding P. R. Identification of locally advanced rectal cancer with low risk of local recurrence. PLoS One 10:e0117141, 2015

15. Tang J. H., An X., Lin X., Gao Y. H., Liu G. C., Kong L. H., Pan Z. Z., Ding P. R. The value of forceps biopsy and core needle biopsy in prediction of pathologic complete remission in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Oncotarget 6:33919-25, 2015

16. Liu G. C., Zhang X., Xie E., An X., Cai P. Q., Zhu Y., Tang J. H., Kong L. H., Lin J. Z., Pan Z. Z., Ding P. R. The Value of Restaging With Chest and Abdominal CT/MRI Scan After Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer. Medicine (Baltimore) 94:e2074, 2015

17. Gao Y. H., Lin J. Z., An X., Luo J. L., Cai M. Y., Cai P. Q., Kong L. H., Liu G. C., Tang J. H., Chen G., Pan Z. Z., Ding P. R. Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial. Int J Radiat Oncol Biol Phys 90:1153-60, 2014

18. Gao Y. H., Zhang X., An X., Cai M. Y., Zeng Z. F., Chen G., Kong L. H., Lin J. Z., Wan D. S., Pan Z. Z., Ding P. R. Oxaliplatin and capecitabine concomitant with neoadjuvant radiotherapy and extended to the resting period in high risk locally advanced rectal cancer. Strahlenther Onkol 190:158-64, 2014

19. You K. Y., Huang R., Ding P. R., Qiu B., Zhou G. Q., Chang H., Xiao W. W., Zeng Z. F., Pan Z. Z., Gao Y. H. Selective use of adjuvant chemotherapy for rectal cancer patients with ypN0. Int J Colorectal Dis, 2014

20. Cai P. Q., Wu Y. P., An X., Qiu X., Kong L. H., Liu G. C., Xie C. M., Pan Z. Z., Wu P. H., Ding P. R. Simple measurements on diffusion-weighted MR imaging for assessment of complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer. Eur Radiol 24:2962-70, 2014

21. Liu G. C., Tang J. H., Wen S. J., Cao H. X., An X., Cai P. Q., Kong L. H., Lin J. Z., Li L. R., Pan Z. Z., Ding P. R. Is early surveillance with CT scan necessary in patients with stage II/III colorectal cancer: A retrospective study. J Surg Oncol, 2013

22. Gao Y. H., An X., Sun W. J., Cai J., Cai M. Y., Kong L. H., Lin J. Z., Liu G. C., Tang J. H., Wu X. J., Chen G., Pan Z. Z., Ding P. R. Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer. J Surg Oncol, 2013

23. An X., Lin X., Wang F. H., Goodman K., Cai P. Q., Kong L. H., Fang Y. J., Gao Y. H., Lin J. Z., Wan D. S., Pan Z. Z., Ding P. R. Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis. Eur J Cancer 49:843-51, 2013

24. Ding P., Liska D., Tang P., Shia J., Saltz L., Goodman K., Downey R. J., Nash G. M., Temple L. K., Paty P. B., Guillem J. G., Wong W. D., Weiser M. R. Pulmonary recurrence predominates after combined modality therapy for rectal cancer: an original retrospective study. Ann Surg 256:111-6, 2012

25. Ding P. R., Tiwari A. K., Ohnuma S., Lee J. W., An X., Dai C. L., Lu Q. S., Singh S., Yang D. H., Talele T. T., Ambudkar S. V., Chen Z. S. The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter. PLoS One 6:e19329, 2011

26. Ding P. R., An X., Cao Y., Wu X. J., Li L. R., Chen G., Lu Z. H., Fang Y. J., Wan D. S., Pan Z. Z. Depth of tumor invasion independently predicts lymph node metastasis in T2 rectal cancer. J Gastrointest Surg 15:130-6, 2011

27. An X., Wang F. H., Ding P. R., Deng L., Jiang W. Q., Zhang L., Shao J. Y., Li Y. H. Plasma Epstein-Barr virus DNA level strongly predicts survival in metastatic/recurrent nasopharyngeal carcinoma treated with palliative chemotherapy. Cancer 117:3750-7, 2011

28. An X., Ding P. R., Wang F. H., Jiang W. Q., Li Y. H. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngeal carcinoma. Tumour Biol 32:317-24, 2011

29. Ding P. R., An X., Zhang R. X., Fang Y. J., Li L. R., Chen G., Wu X. J., Lu Z. H., Lin J. Z., Kong L. H., Wan D. S., Pan Z. Z. Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis 25:1427-33, 2010

30. Ding P. R. , Liska D. , Goodman K. A. , Saltz L. , Guillem J. G. , Paty P. , Temple L. K. F. , Nash G. M. , Wong W. D. , Weiser M. R. : Predictors of site-specific recurrence following combined modality therapy for locally advanced rectal cancer. (Abstract), Journal of Clinical Oncology, 2010 ASCO Annual Meeting. Chicago, 2010, pp 3642

31. An X., Tiwari A. K., Sun Y., Ding P. R., Ashby C. R., Jr., Chen Z. S. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review. Leuk Res 34:1255-68, 2010

32. An X., Ding P. R., Xiang X. J., Wang Z. Q., Wang F. H., Feng F., Jiang W. Q., He Y. J., Xu R. H., Li Y. H. Carcinoembryonic antigen surge in metastatic colorectal cancer patients responding to irinotecan combination chemotherapy. Biomarkers 15:243-8, 2010

33. An X., Ding P. R., Li Y. H., Wang F. H., Shi Y. X., Wang Z. Q., He Y. J., Xu R. H., Jiang W. Q. Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers 15:516-22, 2010

Updated May 2020

Dr. Pan Zhi-zhong is the Professor and Director of the Colorectal Department of Sun Yat-sen University Cancer Centre (SYSUCC). He is also the director of the Chinese Doctor’s Association of Laparoscopic Surgeon Training Base, and the vice-president of the Chinese Research Hospital Association Oncology Surgery Committee, the Chinese Medical Doctor Association Anorectal Surgery Branch Tumor Metastasis Committee, and Guangdong’s Provincial Health Management Society Cancer Prevention and Treatment Committee. He is also the Chairman of China’s Colorectal Cancer MDT Alliance.  Dr. Pan has published more than 60 papers in top journals, including J Nat Cancer Inst, and Ann Oncol. Dr. Pan has extensive experience in laparoscopic surgery, transanal minimally invasive surgery (TEM), comprehensive treatment of liver metastases, and stromal tumor treatment.

Translational and clinical research of colorectal cancer with liver metastasis. Promoting the standardization of laparoscopic surgery and the treatment of colorectal cancer.

Dr. Pan received his Doctoral Degree in clinical medicine from Sun Yat-sen University. He completed his training as a surgeon fellow in Australia Adeladie Royal Hospital, Elizabeth Queens Hospital, France Paul Brousse Hospital, and Hong Kong Guanghua Hospital.

1. Liu GC#, Liu RY#, Yan JP, An X, Jiang W, Ling YH, Chen JW, Bei JX, Zuo XY, Cai MY6, Liu ZX, Zuo ZX, Liu JH, Pan ZZ*, Ding PR*. The Heterogeneity Between Lynch-Associated and Sporadic MMR Deficiency in Colorectal Cancers. J Natl Cancer Inst (IF:12.589). 2018 Feb 20. doi: 10.1093/jnci/djy004.

2. Zhang RX#, Wu XJ#, Wan DS, Lu ZH, Kong LH, Pan ZZ*, Chen G*. Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol. (IF：11.855) 2012;23(5):1348-53.

3. Peng J, Wang Y, Zhang R, Deng Y, Xiao B, Ou Q,2, Sui Q, Xu J, Qin J, Lin J, Pan Z. Immune Cell Infiltration in the Microenvironment of Liver Oligometastasis from Colorectal Cancer: Intratumoural CD8/CD3 Ratio Is a Valuable Prognostic Index for Patients Undergoing Liver Metastasectomy. Cancers (Basel). 2019 Dec 2;11(12). (IF:6.612)

4. Tang JH, Jiang W, Liu D, Luo J, Wu XJ, Pan ZZ, Ding PR Li YQ. The comprehensive molecular landscape of the immunologic co-stimulator B7 and TNFR ligand receptor families in colorectal cancer: immunotherapeutic implications with microsatellite instability. Oncoimmunology. 2018 Jul 11;7(10) (IF: 5.503)

5. Lin JZ#, Peng JH#, Qdaisat A#, Lu ZH, Wu XJ, Chen G, Ding PR, Li LR, Gao YH, Zeng ZF, Wan DS, Pan ZZ*. Preoperative chemoradiotherapy creates an opportunity to perform sphincter preserving resection for low-lying locally advanced rectal cancer based on an oncologic outcome study. Oncotarget. (IF:5.168) 2016 30;7(35):57317-57326.

6. Tang JH#, An X#, Lin X#, Gao YH, Liu GC, Kong LH, Pan ZZ*, Ding PR*. The value offorceps biopsy and core needle biopsy in prediction of pathologic completeremission in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Oncotarget. (IF:5.168)2015,6（32）：33919-33925.

7. Peng JH#, Fang YJ#, Li CX#, Ou QJ#, Jiang W, Lu SX, Lu ZH, Li PX, Yun JP, Zhang RX, Pan ZZ*, Wan DS*. A scoring system based on artificial neural network for predicting 10-year survival in stage II A colon cancer patients after radical surgery. Oncotarget. (IF:5.168) 2016;7(16):22939-47.

Updated May 2020

1965 Graduated from Sun Yat-Sen University

1989 – 1991 Sponsored by the WHO scholarship, Dr. Wan received specialty training in gastrointestinal cancer treatment in the United States.

Last updated on: September, 2014

Multiple disciplinary therapy model of colorectal cancer and molecular mechanism of tumor metastasis.

Tertiary
Sun Yat-Sen University of Medical Science (SYSU)
Clinical Medicine Department
MBBS obtained in1998 

Internship
1997 First Affiliated Hospital of SYSU
Medical Science Medicine 

M.S. in Surgery
1998-2000
Thesis: “Comparison of MeshPlug Hernia Repair and Bassini Repair”
Supervisor: Prof Yihua Huang

M.D., Ph.D. in Oncology
2002-2005 SYSUC
Thesis: “Relationship between Lymphangiogenesis and Local Invasion, Lymphatic Metastasis in ColorectalCarcinoma”
Supervisor: Prof Desen Wan Sun Yat-Sen University of Medical ScienceSun Yat-Sen University of Medical ScienceSun Yat-Sen University of Medical Science

1. Ian R. Watson, Liren Li, Peter K. Cabeceiras, et al. The RAC1 P29S Hotspot Mutation in Melanoma Confers Resistance to Pharmacological Inhibition of RAF. Cancer Research, 2014 (accepted).

2. Wang G, Gao Y, Li L, Jin G, Cai Z, Chao JI, Lin HK. K63-linked ubiquitination in kinase activation and cancer. Front Oncol. 31, 2(5): 1-13, 2012.

3. Ding Z, Wu CJ, Jaskelioff M, Ivanova E, Kost-Alimova M, Protopopov A,Chu GC, Wang G, Lu X, Labrot ES, Hu J, Wang W, Xiao Y, Zhang H, Zhang J, Zhang J, Gan B, Perry SR, Jiang S, Li L, Horner JW, Wang YA, Chin L, DePinho RA. Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell. 148(5): 896-907, 2012.

4. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K,Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M,Ladbury JE, Davies MA, Gershenwald JE, Wagner SN, Hoon DS, Schadendorf D, Lander ES, Gabriel SB, Getz G, Garraway LA, Chin L. A landscape of driver mutations in melanoma. Cell. 150(2):251-63, 2012.

5. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 487(7407):330-7, 2012.

6. Li LR;Fang YJ;Pan ZZ;Wu XJ;Wan DS;Hardingham JE;Rieger N. Length of lymphangiogenesis in the rectal tissues distal to rectal cancer. Tumour Biol. 31(6): 667-71, 2010.

7. Fang YJ;Pan ZZ;Li LR;Lu ZH;Zhang LY;Wan DS. MMP7 expression regulated by endocrine therapy in ERbeta-positive colon cancer cells. Journal of experimental & clinical cancer research, 2009, 28: 132.

8. Li LR, Wan DS, Pan ZZ, et al. Expression of hTERT in activated lymphocytes using real-time RT-PCR. Journal of Colorectal & Anal Surgery, 2007: 7-10.

9. Li LR, Wan DS, Pan ZZ, et al. Prognostic effect of lymphatic spreading of colorectal cancer.GuangdongProvinceJournal of Medicine, 2006: 1819-1821.

10. Li LR, Wan DS, Pan ZZ, et al. Predictive mathematical model for lymphatic metastasis of colorectal cancer. Bulletin of Chinese Cancer, 2006: 876-878.

11. Li LR, Wan DS, Pan ZZ, et al. Effect of clinicopathologic parameters on lymphatic metastasis of colorectal cancer.ChinaTropical Medicine, 2006:1160-1163.

12. Li LR, Wan DS, Pan ZZ, et al. Clinical feature and treatment strategy of anal canal adenocarcinoma. Chinese Journal of Gastrointestinal Surgery, 2006: 402-404.

13. Li LR, Wan DS. Advance in lymphangiogenesis of colorectal cancer, 2006: 382-384.

14. Li LR, Wan DS, Pan ZZ, et al. Relationship between VEGFR-3 and Prox1 incolorecal cancer.GuangdongProvinceJournal of Medicine, 2005: 1488-1490.

15. Li LR, Pan ZZ, Nick Rieger, et al. Clinical significance of expression of hTERT in colorectal cancer. Aizheng, 2004: 1502-1507.

16. Li LR, Huang YH. Comparison between tension-free inguinal hernia repair and Bassini repair. Chinese Journal of General Surgery, 2001: 47-49.

Book chapters

1. Li LR, Wan DS. Appendix adenoma and carcinoid. Colorectal Cancer, Peking: Chinese Medical Science Publishing House, 2004.

2. Li LR, Wan DS. Large bowel perforation. Stoma rehabilitation and treatment: theory and practice, Peking: Chinese Medical Science Publishing House, 2006.

3. Li LR, Wan DS.Melanoma in anorectum. Colorectal cancer, Peking: Peking University MedicalPress, 2008.

Last updated on: July, 2014

1998 Graduated from Sun Yat-Sen University 

2001 – 2003 Fellowship Trainee, the University of Adelaide and the Queen Elizabeth Hospital, Australia 2003 PhD in Medicine Last updated on: May, 2014  

Dr. Wu Xiaojun, MD of Clinical Oncology, is an attending professor and associate chief physician for Department of Colorectal Surgery at Sun Yat-sen University Cancer Center. He graduated from the Department of Clinical Medicine in former Sun Yat-sen University of Medical Sciences in 1996.

Currently he is engaged in the diagnosis and treatment of gastroenteric tumor and specializes in combination therapy for colorectal cancer, diagnosis and treatment of gastrointestinal stromal tumor as well as the prevention and treatment of community oncology. Meanwhile he is the member of the Guangdong Standing Committee of Colorectal Cancer CACA, member of Colorectal and Anal Surgery Branch of Guangdong Medical Association and member of the Standing Committee of Tumor Prevention and Treatment, Guangdong Health Management Association. After graduation, he headed for Yunnan Provincial People's Hospital to support the construction of the border areas by dedicating himself to surgical oncology. In 2006, appointed by Department of Health of Guangdong Province and Sun Yat-sen University Cancer Center, Dr. Wu Xiaojun got involved in the medical support program of Guangdong “Health Talent Support for Mountain Area” and served as the Vice President of Zijin County People's Hospital of Heyuan to take charge of medical treatment, scientific research and teaching.

By 2014, he has presided over and participated in 12 research projects and 4 global clinical trials, mainly centered on research work related to liver metastasis of colorectal cancer, chemoradiotherapy sensitivity, prognosis of immunologic function and curative effect as well as gastrointestinal stromal tumor. He has composed and published 65 papers, including 20 SCI papers, and edited 7 monographs, such as Book Series of Community Prevention and Treatment of Tumors -- Diet and Cancer, Community Oncology, Colorectal Cancer, Stoma Therapy and Rehabilitation - Theory and Practice, Colorectal Carcinoma, Modern Clinical Nursing Practice of Wound and Stoma and Medical Oncology. The project he partook in, Application Research of Community Prevention and Comprehensive Treatment for Colorectal Cancer, won the second Science and Technology Award of Chinese Anti-Cancer Association and the second Prize for Progress in Science and Technology of Guangdong Province. Additionally, Dr. Wu Xiaojun serves as the physician of medical evaluation for Glivec International Patient Assistance Program (GIPAP) and Cancer Foundation of China SPAP (Sutent Patient Assistance Program).

Combination therapy for colorectal cancer, diagnosis and treatment of gastrointestinal stromal tumor as well as the prevention and treatment of community oncology

1991-1996 Department of Clinical Medicine in former Sun Yat-sen University of Medical Sciences 1996-2000 Department of Surgical Oncology in Yunnan Provincial People's Hospital 2000-2003 Master’s degree student of Oncology in Zhongshan School of Medicine, SYSU2003-2012 Worked in Sun Yat-sen University Cancer Center (2007-2010 doctoral student of Oncology)2006 Supported Zijin County People's Hospital of Guangdong, served as Vice President, and took charge of clinical work, teaching and scientific research2009 Served as Secretary of Colorectal Surgery 2012 Attended the short-term training in MGH, the United States

1. Hospital-based colorectal cancer survival trend of different tumor locations from 1960s to 2000s. PLoS One. 2013 Sept. 12;8(9).

2. Study on associated biomarkers influencing recurrence, metastasis and prognosis in patients with gastrointestinal stromal tumors after complete resection. Chinese Journal of Gastrointestinal Surgery. 2013 Mar;16(3):242-6.

3. Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol. 2012 May;23(5):1348-53.

4. Circulating antibodies to carcinoembryonic antigen related to improved recurrence-free survival of patients with colorectal carcinoma. J Int Med Res. 2011;39(3):838-845.

5. The effect of COX-2 inhibitor on capecitabine-induced hand-foot syndrome in patients with stage II/III colorectal cancer: a phase II randomized prospective study. J Cancer Res Clin Oncol. 2011 Jun;137(6):953-957.

6. The prognostic significance of peripheral T-lymphocyte subsets and NK cells in patients with colorectal cancer. Hepato-Gastroenterology. 2009 Oct.56:1310-1315.

7. Prognostic factors in surgically managed gastrointestinal stromal tumors. J Int Med Res. 2012;40(5):1904-11.

8. Surgical treatment for 140 patients with gastric stromal tumors. Chinese Journal of Gastrointestinal Surgery. 2010 Jun;13(6):417-20.